RCS - Ondine Biomedical - Ondine starts first UK health economics study

Ondine BiomedicalAnnouncement

05/03/2024 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240305:nRSE6313Fa&default-theme=true

RNS Number : 6313F  Ondine Biomedical Inc.  05 March 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health
economic analysis of Ondine's Steriwave light-activated antimicrobial to
reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health
Innovation Yorkshire and Humber are partnering with the York Health Economics
Consortium (YHEC) to evaluate the use of Ondine's light-activated
antimicrobial, Steriwave®, to reduce the incidence of surgical site
infections (SSIs).

SSIs are one of the most common healthcare-associated infections (HAIs) and
affect one in every 20 patients who undergo a surgical procedure in the NHS.
SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS
England is over £2 billion a year. These costs are expected to rise as
growing rates of antimicrobial resistance (AMR) make the current standard of
care - the antibiotic mupirocin -  less effective.

 

Steriwave uses a proprietary photosensitizer, which is activated by a specific
wavelength of red light, to eliminate infection-causing pathogens in the nose.
The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA
which are known to cause SSIs. Steriwave eliminates these pathogens, including
superbugs, in a painless five-minute treatment and prevents them from
spreading and causing infections. Importantly, unlike today's antibiotics, the
use of Steriwave does not trigger antimicrobial resistance.

The health economic analysis is being undertaken by YHEC, an internationally
renowned provider of health economics evaluations, and will supplement the
ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves
500 elective hip and knee surgery patients over a period of six months. The
findings will be used to support adoption of Steriwave across the NHS.

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation
at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be
partnering with Ondine and the YHEC on this economic analysis to support the
promising results of the Steriwave pilot we have seen so far. The data from
the health economic analysis will support the results of our pilot, and we
hope to be able to share these later this year."

Helen Hoyland, Head of Health Innovation Yorkshire & Humber's Office of
Life Sciences portfolio, said: "Health Innovation Yorkshire and Humber
(formerly the Academic Health Science Network for the region) is pleased to be
supporting this evaluation. We are commissioned by the Office of Life Sciences
to support real-world evidence generation. We will work with the innovators
and the Trust to publish the evaluation data, and then subsequently look to
support further opportunities for the spread and adoption of Steriwave,
working alongside the West Yorkshire Innovation Hub".

Steriwave is also being used in major hospitals across Canada, including
Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the
Mazankowski Alberta Heart Institute. Research recently published by VGH in the
Canadian Journal of Surgery showed that the use of Steriwave in patients
undergoing spine surgery resulted in a 66.5% reduction in post-surgical
infection rates and $2.5 million in annual savings.(( i  (#_edn1) )) No
serious adverse events have ever been reported from Steriwave treatment.

**ENDS**

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About York Economics Consortium

York Health Economics Consortium (YHEC) is a health economics consulting
company owned by the University of York. It provides a range of services,
including economic modelling, literature searching, systematic reviews,
network meta-analyses, patient-reported outcomes, service review and applied
research and training to the NHS and the pharmaceutical and healthcare
industries. YHEC also carries out work for a range of clients outside the
health sector, including Local Authorities and the voluntary sector. Current
clients include: the National Institute for Health and Care Excellence (NICE),
NHS England, a range of local NHS trusts and several large multinational
pharmaceutical, device, digital health and nutrition companies.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the
field of light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection platform, in various stages of
development. Ondine's nasal photodisinfection system has a CE mark in Europe
and the UK and is approved in Canada and several other countries under the
name Steriwave®. In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

About Steriwave®

Ondine's Steriwave Nasal Photodisinfection System is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
pathogens. The photodisinfection treatment is carried out by a trained
healthcare professional and is an easy-to-use, painless, two-step
process. The photosensitizer is applied to each nostril using a nasal swab,
followed by illumination of the area with a specific wavelength of red light
for less than five minutes. The light activates the photosensitizer, causing
an oxidative burst that is lethal to all types of pathogens. A key benefit of
this approach, unlike with antibiotics, is that pathogens do not develop
resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of healthcare-associated infections, including surgical site
infections (SSIs). Nasal decolonization is recommended in the 2016 WHO Global
guidelines for the prevention of SSIs,(( ii  (#_edn2) )) and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical procedures.(( iii  (#_edn3)
)) However, there is a growing need to reduce traditional antibiotic use as
resistance rates have been reported as high as 81%.(( iv  (#_edn4) ))

 

 

 i  (#_ednref1) Eryck Moskven, Daniel Banaszek, Eric C. Sayre, Aleksandra
Gara, Elizabeth Bryce, Titus Wong, Tamir Ailon, Raphaële Charest-Morin,
Nicolas Dea, Marcel F. Dvorak, Charles G. Fisher, Brian K. Kwon, Scott
Paquette and John T. Street. Can J Surg November 15, 2023 66 (6) E550-E560;
DOI: https://doi.org/10.1503/cjs.016922 (https://doi.org/10.1503/cjs.016922)

 ii  (#_ednref2)
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 iii  (#_ednref3) Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies
to prevent surgical site infections in acute-care hospitals: 2022 Update.
Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

 iv  (#_ednref4) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of
MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKPBNCBKKQNK